Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Veerman

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1996
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumorsG Veerman, V W Ruiz van Haperen, J B Vermorken, et al.
British Journal of Cancer|June 12, 2003
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell linesA M Bergman, H M Pinedo, I Talianidis, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell linesC J van Moorsel, G Veerman, V W Ruiz van Haperen, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Mechanisms of synergism between gemcitabine and cisplatinC J van Moorsel, G Veerman, J B Vermorken, et al.
Biochemical Pharmacology|May 2, 2001
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell linesA M Bergman, B Munch-Petersen, P B Jensen, et al.
Cancer Research|August 1, 1994
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780V W Ruiz van Haperen, G Veerman, S Eriksson, et al.
Biochemical Pharmacology|February 5, 1999
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell linesC J van Moorsel, H M Pinedo, G Veerman, et al.
Biochemical Pharmacology|February 5, 1999
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseA M Bergman, H M Pinedo, A P Jongsma, et al.
Nucleosides, Nucleotides & Nucleic Acids|October 27, 2006
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunitsK Smid, A M Bergman, P P Eijk, et al.
Biochimica Et Biophysica Acta|March 4, 2000
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell linesC J van Moorsel, A M Bergman, G Veerman, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|January 1, 1996
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumorsG Veerman, V W Ruiz van Haperen, J B Vermorken, et al.
British Journal of Cancer|June 12, 2003
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell linesA M Bergman, H M Pinedo, I Talianidis, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell linesC J van Moorsel, G Veerman, V W Ruiz van Haperen, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Mechanisms of synergism between gemcitabine and cisplatinC J van Moorsel, G Veerman, J B Vermorken, et al.
Biochemical Pharmacology|May 2, 2001
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell linesA M Bergman, B Munch-Petersen, P B Jensen, et al.
Cancer Research|August 1, 1994
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780V W Ruiz van Haperen, G Veerman, S Eriksson, et al.
Biochemical Pharmacology|February 5, 1999
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell linesC J van Moorsel, H M Pinedo, G Veerman, et al.
Biochemical Pharmacology|February 5, 1999
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseA M Bergman, H M Pinedo, A P Jongsma, et al.
Nucleosides, Nucleotides & Nucleic Acids|October 27, 2006
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunitsK Smid, A M Bergman, P P Eijk, et al.
Biochimica Et Biophysica Acta|March 4, 2000
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell linesC J van Moorsel, A M Bergman, G Veerman, et al.
Pageof 4